Dianthus Therapeutics, Inc. research snapshot
DNTH AI stock analysis reads Dianthus Therapeutics as a clinical-stage biotechnology company developing next-generation therapies for severe autoimmune diseases, with lead candidate claseprubart (DNTH103), an anti-active C1s complement antibody, and second candidate DNTH212, a bifunctional Type 1 IFN and B cell modulator. As of the August 2026 data cutoff, DNTH traded near $105.88 with a verified market capitalization near $5.79 billion. Dianthus is pre-revenue, holds about $1.11 billion in cash and short-term investments, and has advanced claseprubart into Phase 3 in generalized myasthenia gravis and CIDP, with a Phase 2 program in multifocal motor neuropathy. The stock trades just below its 52-week high of $114.55 after the Phase 3 EMERGE launch in July 2026 and a strong 2026 run. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$105.88
Market cap
$5.79 billion
AI score
52 / 100
Rating
Clinical-stage autoimmune biotech with a broadened pipeline, pre-revenue, high binary risk
Trend status
Near the $114.55 52-week high on Phase 3 momentum and all-Buy analyst consensus
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Dianthus is developing claseprubart, a potentially best-in-class anti-C1s antibody for complement-mediated autoimmune disease, now in Phase 3 for gMG and CIDP and Phase 2 for MMN, plus DNTH212, a bifunctional fusion protein targeting Type 1 IFN and B cell pathways. Both assets address validated mechanisms with subcutaneous self-administration convenience. | Medium |
| Moat | Moat potential comes from differentiated product design (YTE half-life extension, active C1s selectivity, once-monthly subcutaneous dosing), IP protection, and a broadened neuromuscular franchise. Moat is unproven until clinical and commercial validation, and class-wide read-through risk remains after the Sanofi riliprubart CIDP halt. | Low-medium |
| Management | CEO Marino Garcia and the team have secured about $1.1 billion in cash, made an early GO decision in the CAPTIVATE CIDP program, initiated Phase 3 EMERGE in gMG, and managed the June 2026 Sanofi class read-through. The track record is early stage with no approved product to date. | Medium |
| Financial trend | Pre-revenue with revenue of about $2 million in 2025 and roughly $40 to $50 million in quarterly operating losses. Cash and short-term investments of about $1.11 billion provide runway beyond the near-term catalysts, with debt near zero (0.11% debt/equity). | High |
| Valuation | At $105.88, DNTH trades at roughly 4.9x book value with a $4.74 billion enterprise value against $1.11 billion in cash, an EV-to-cash multiple near 4.3x. Valuation is driven by pipeline probability-adjusted value rather than earnings, with analyst price targets ranging from $98 to $200 and an average near $129 to $135. | Medium |
| Technical trend | Near the $114.55 52-week high after a sustained 2026 rally, including a 12% jump on the Phase 3 EMERGE kickoff in July. Well above the $18.08 52-week low but extended from breakout levels after a move of more than 400% over one year. | Medium |
| Risk level | High. Main risks include clinical trial failure or delay in gMG, CIDP, or MMN, regulatory setbacks, class-wide complement inhibitor read-through, cash burn and future dilution, binary data-event volatility, and the long runway to Phase 3 data in the second half of 2028. | High |
| AI confidence | High for descriptive facts, financial position, and pipeline milestones; medium for scenario valuations and technical levels; low for binary clinical outcome prediction. | Medium data confidence |
| Investment certainty | Low to medium. This page frames scenarios and monitoring rules, not a buy or sell instruction. Clinical-stage biotech requires a higher risk tolerance and position sizing for binary outcomes. | Low-medium |
DNTH AI stock forecast
The DNTH AI stock forecast uses scenario math around the $105.88 quote, the $1.11 billion cash position, the $4.74 billion enterprise value, and analyst consensus price targets near $129 to $135. Valuation depends mainly on Phase 3 data readouts, regulatory progress, and competitive dynamics rather than earnings growth.
$160 to $200
More likely if CAPTIVATE Part B top-line data and the Phase 2 MoMeNtum MMN readout in the fourth quarter of 2026 are positive, EMERGE enrollment and interim signals stay clean, DNTH212 healthy-volunteer data look good, and the company becomes an attractive acquisition target for pharma seeking autoimmune assets. This range tracks the higher analyst targets, including Guggenheim at $200.
$115 to $145
More likely if trials advance on schedule with no major safety or efficacy setbacks, the early August 2026 earnings report and financing stay steady, and the stock trades toward the analyst consensus near $129 to $135. This range sits just above the recent 52-week high zone.
$55 to $80
More likely if a negative class read-through such as the June 2026 Sanofi CIDP halt hits again, CAPTIVATE Part B or MMN data disappoint, regulatory feedback slows enrollment, or the company needs dilutive financing before key catalysts. The June 2026 trough after the Sanofi news was around $68 to $73.
DNTH AI technical analysis
DNTH AI technical analysis reflects a stock that has rallied from $18.08 to a 52-week high of $114.55, driven by positive clinical data, a June 2026 class read-through and recovery, and the July 2026 Phase 3 EMERGE launch. As of the August 2026 data cutoff, DNTH trades near $105.88 with strong but extended momentum and elevated event risk around the early August earnings report.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $105.88 | Intraday quote snapshot in the August 3, 2026 US session; the July 31 close was $106.92. Quotes were captured as of the August 4, 2026 data cutoff. |
| Near support | $98 to $102 | The $100 psychological level and the July consolidation zone mark the first support area after the pullback from the $114.55 high. |
| Breakout support | $82 to $92 | The mid-$80s to low-$90s zone acted as the launchpad for the July rally above $100. A close below this zone would signal the recent momentum setup has broken. |
| Major support | $68 to $73 | The June 2026 trough after the Sanofi CIDP read-through. A close below this area would suggest the broader uptrend has reversed. |
| Near resistance | $112 to $115 | The 52-week high of $114.55 and the $112 to $115 zone represent immediate resistance. |
| Next resistance | $128 to $135 | The analyst consensus price target zone (Yahoo $128.58, StockAnalysis $129.75, Google Finance $135.29) marks the next resistance area. |
| Momentum | Strong but extended | DNTH is up about 417% over one year and 159% year to date, indicating strong momentum but also elevated mean-reversion risk after a sustained run. |
| Volume | Average volume near 1.0 to 1.5 million shares | Volume expands sharply on clinical data and analyst news, creating gap risk around binary events such as the early August earnings report. |
| Volatility | High, typical of clinical-stage biotech | Google Finance beta is 1.20, while Yahoo and StockAnalysis report a much lower five-year monthly beta near 0.09. DNTH can move 10 to 20 percent or more on single data releases or regulatory news. |
| Invalidation | Close below $82 | A decisive close below the $82 to $92 breakout zone would invalidate the current positive momentum setup, with a move below $68 negating the broader uptrend. |
DNTH AI trading strategy
The DNTH AI trading strategy is a rules-based research framework for monitoring a clinical-stage autoimmune biotech with Phase 3 catalysts in gMG and CIDP and a Phase 2 readout in MMN. It is not personal advice and should be paired with clinical trial updates, cash runway analysis, the Q2 2026 earnings report, position sizing appropriate for binary risk, and a defined invalidation level.
Monitor the early August 2026 Q2 earnings report, CAPTIVATE Part B top-line guidance by the end of 2026, Phase 2 MoMeNtum MMN data in the fourth quarter of 2026, and EMERGE enrollment updates. Position sizing should reflect the binary nature of clinical data events, and analyst updates and trial disclosures should be used as informational inputs.
Clinical-stage biotech can gap up or down 10 to 20 percent or more on data. Define maximum position size and portfolio allocation before catalysts. A failed readout in a lead program is a thesis-ending event.
After positive data, watch for volume confirmation and follow-through above the $112 to $115 resistance zone. After negative data, the $82 to $92 breakout support becomes the critical test, with $68 to $73 as the deeper marker. The Sanofi CIDP read-through in June 2026 is a reminder that class-wide events can hit the stock even when company-specific data have not changed.
Do not chase extended rallies post-catalyst without a pullback to a defined entry zone. Biotech stocks often give back part of post-data gains.
Track CAPTIVATE Part B and EMERGE enrollment, clinical holds or safety signals, cash burn and dilution risk, partnership or M&A speculation, and the gMG, CIDP, and MMN competitive field including argenx and UCB programs and the status of Sanofi after the riliprubart halt.
Reduce exposure if cash runway falls, if a competitor reads positive data in the same indication, or if insider selling accelerates after the 2026 rally. The Q2 2026 earnings report should confirm cash position and operating burn.
Investment research summary
Dianthus is engineering better antibodies for autoimmune patients. Customers, meaning patients, physicians, and payers, pay for convenient, effective, and safe treatments that improve on current standards such as efgartigimod and IVIg, with once-monthly subcutaneous self-administration as a key convenience.
The moat exists on paper until clinical and commercial validation. Differentiated product design (YTE half-life extension, active C1s selectivity, subcutaneous dosing) and patent protection provide potential, but argenx, UCB, and others are already commercial or late-stage in overlapping indications, and the Sanofi riliprubart CIDP halt shows the class can suffer read-through.
The thesis fails if claseprubart Phase 3 or Phase 2 readouts miss, if safety signals emerge, if a class-wide event such as the Sanofi CIDP halt repeats, if commercial reimbursement is poor, or if the company needs dilutive financing before key catalysts.
Management should be judged by clinical execution, capital allocation across the three neuromuscular programs and DNTH212, partnership and regulatory strategy, and whether they preserve the $1.11 billion cash position while advancing catalysts.
Autoimmune disease therapies represent a large and growing market with significant unmet need. The complement system and Type 1 IFN and B cell pathways are validated mechanisms, and Dianthus sits at the intersection of targeted biologics and convenient subcutaneous administration.
At roughly $105.88 and a $4.74 billion enterprise value, DNTH prices in meaningful Phase 3 and commercial success probability. Margin of safety is limited for a pre-revenue biotech, and a deeper value entry would require a significant pullback on temporary negative sentiment or a class read-through.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DNTH price | $105.88 (intraday August 3, 2026); July 31 close $106.92 | Google Finance quote snapshot | August 4, 2026 |
| Market capitalization | $5.79 billion, verified as $105.88 x 54.67 million shares (deviation 0.03%) | financial_rigor.py market cap verification | August 4, 2026 |
| Enterprise value | $4.74 billion (market cap less cash and short-term investments) | Yahoo Finance statistics | August 4, 2026 |
| Cash and short-term investments (mrq) | $1.11 billion | Yahoo Finance balance sheet | August 4, 2026 |
| Total debt/equity (mrq) | 0.11% | Yahoo Finance balance sheet | August 4, 2026 |
| Net income (TTM) | -$173.66 million | Yahoo Finance income statement | August 4, 2026 |
| Diluted EPS (TTM) | -$4.24 (Yahoo Finance); -$4.17 (StockAnalysis) | Yahoo Finance statistics | August 4, 2026 |
| Revenue | $1.34 million (TTM); $2.04 million for 2025 | StockAnalysis financial statements | August 4, 2026 |
| Shares outstanding | 54.67 million | Google Finance summary | August 4, 2026 |
| 52-week range | $18.08 to $114.55 | Google Finance summary | August 4, 2026 |
| Analyst consensus | Strong Buy from 11 to 15 analysts; average 12-month target $128.58 to $135.29 across Yahoo, StockAnalysis, and Google Finance | Google Finance analyst ratings | August 4, 2026 |
| Lead program | Claseprubart (DNTH103): anti-active C1s antibody. Phase 3 EMERGE in gMG (about 195 patients, top-line 2H 2028); Phase 3 CAPTIVATE in CIDP (Part B top-line guidance by YE 2026); Phase 2 MoMeNtum in MMN (top-line Q4 2026) | Dianthus Therapeutics company website | August 4, 2026 |
| Second program | DNTH212: bifunctional BDCA2 and BAFF/APRIL fusion protein. Phase 1 with priority indications Sjogrens disease, SLE, and dermatomyositis; healthy-volunteer data expected in 2H 2026 | Dianthus Therapeutics company website | August 4, 2026 |
| Class read-through event | Sanofi halted the MOBILIZE Phase 3 study of riliprubart in refractory CIDP for futility on June 10, 2026 (NCT06290128); DNTH fell about 16 to 19 percent before recovering | Sanofi press release and BioPharma Dive | August 4, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell DNTH stock. Forecast scenarios are based on available public data, clinical trial disclosures, analyst estimates, and stated assumptions as of the data cutoff date and may be wrong. Clinical-stage biotechnology investments carry high risk, including the potential for complete loss of capital. Always verify current filings, clinical trial updates, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
